Investors who purchased Aardvark Therapeutics, Inc. common stock issued under or traceable to its February 13, 2025 initial public offering registration statement and prospectus, or other securities between February 13, 2025, and May 14, 2026, inclusive, have until October 13, 2026, to ask a court to appoint them lead plaintiff in a securities class action. The lawsuit alleges that Aardvark and other defendants failed to disclose that ARD-101 was less safe than represented, overstated the drug candidate’s clinical, regulatory and commercial prospects, and made materially false or misleading statements. The complaint claims investors suffered losses when the alleged truth entered the market. No class has been certified. Investors may seek information or join under a contingency fee arrangement, retain their own counsel, remain absent class members, or take no action; any potential recovery does not depend on serving as lead plaintiff.